

Supplementary Table 1: Frequency distribution of selected variables in glioma patients and cancer-free controls in combined subjects.

Variables	Cases (n = 314)	Controls (n = 380)	P-value*
Age (months)	70.5 ± 48.4	64.2 ± 37.4	0.461
<60	135 (42.99)	174 (45.79)	
≥60	179 (57.01)	206 (54.21)	
Sex			0.379
Female	146 (46.50)	164 (43.16)	
Male	168 (53.50)	216 (56.84)	
Subtypes			
Astrocytic tumors	214 (68.15)	–	
Ependymoma	61 (19.43)	–	
Neuronal and mixed neuronal–glial tumors	25 (7.96)	–	
Embryonal tumors	12 (3.82)	–	
NA	2 (0.64)	–	
WHO stages			
I	151 (48.09)	–	
II	73 (23.23)	–	
III	36 (11.46)	–	
IV	53 (16.88)	–	
NA	1 (0.32)	–	

*Two-sided χ^2 -test for distributions between glioma patients and cancer-free controls. NA: Not available; SD: Standard deviation.

Supplementary Table 2: Stratification analysis of risk genotypes with glioma susceptibility.

	rs2298881				rs11615				Risk genotypes			
	(cases/controls)		AOR (95%		(cases/controls)		AOR (95%		(cases/controls)		AOR (95%	
Variables	CC	CA/AA	CI)*	P-value*	GG	GA/AA	CI)*	P-value*	0–1	2–3	CI)*	P-value*
Age (months)												
<60	54/60	81/114	0.79 (0.50–1.26)	0.325	72/106	63/68	1.36 (0.86–2.15)	0.183	24/42	111/132	1.47 (0.84–2.57)	0.181
≥60	78/79	101/127	0.80 (0.53–1.20)	0.276	99/125	80/81	1.24 (0.83–1.86)	0.301	37/54	142/152	1.37 (0.85–2.21)	0.194
Gender												
Females	55/64	91/100	1.08 (0.68–1.71)	0.755	78/97	68/67	1.23 (0.79–1.94)	0.363	26/44	120/120	1.71 (0.99–2.96)	0.056
Males	77/75	91/141	0.64 (0.42–0.97)	0.037	93/134	75/82	1.31 (0.87–1.98)	0.194	35/52	133/164	1.20 (0.74–1.96)	0.455
Subtypes												
Astrocytic tumors	99/139	115/241	0.69 (0.49–0.97)	0.034	115/231	99/149	1.31 (0.93–1.84)	0.126	42/96	172/284	1.38 (0.92–2.09)	0.124
Ependymoma	20/139	41/241	1.07 (0.60–1.93)	0.813	37/231	24/149	1.03 (0.59–1.82)	0.906	9/96	52/284	1.92 (0.90–4.08)	0.090
Neuronal and mixed	7/139	18/241	1.49 (0.60–3.67)	0.388	15/231	10/149	1.05 (0.46–2.41)	0.907	8/96	17/284	0.71 (0.30–1.70)	0.438
Embryonal tumors	6/139	6/241	0.65 (0.20–2.11)	0.475	2/231	10/149	7.06 (1.51–33.07)	0.013	2/96	10/284	1.68 (0.36–7.92)	0.513
Clinical stage												
I	72/139	79/241	0.65	0.030	76/231	75/149	1.50	0.037	28/96	123/284	1.47	0.110

			(0.44–0.96)			(1.02–2.20)				(0.92–2.36)			
II	21/139	52/241	1.43 (0.82–2.47)	0.205	44/231	29/149	1.02 (0.61–1.71)	0.928	16/96	57/284	1.20 (0.66–2.19)	0.551	
III	16/139	20/241	0.66 (0.33–1.34)	0.251	23/231	13/149	0.91 (0.45–1.87)	0.800	6/96	30/284	1.69 (0.68–4.21)	0.261	
IV	23/139	30/241	0.82 (0.45–1.49)	0.518	27/231	26/149	1.40 (0.78–2.53)	0.265	11/96	42/284	1.25 (0.61–2.57)	0.535	
I+II	93/139	131/241	0.83 (0.59–1.17)	0.286	120/231	104/149	1.34 (0.96–1.87)	0.089	44/96	180/284	1.39 (0.93–2.08)	0.109	
III+IV	39/139	50/241	0.76 (0.48–1.22)	0.253	50/231	39/149	1.18 (0.74–1.88)	0.500	17/96	72/284	1.43 (0.80–2.54)	0.231	*Adjusted for age and sex, omitting the corresponding stratify factor.

ponding stratify factor. CI: Confidence interval; OR: Odds ratio.

Supplementary Table 3: Stratification analysis between *XPF* rs2276466 C>G polymorphism and glioma risk.

Variables	Cases/Controls		Crude OR (95% CI)	P-value	Adjusted OR*	
	CC	CG/GG			(95% CI)	P-value*
Age (months)						
<60	67/95	66/79	1.19 (0.75–1.86)	0.463	1.18 (0.75–1.86)	0.476
≥60	112/128	65/78	0.95 (0.63–1.44)	0.818	0.95 (0.63–1.44)	0.808
Gender						
Females	81/91	63/73	0.97 (0.62–1.52)	0.893	1.03 (0.65–1.64)	0.887
Males	98/132	68/84	1.09 (0.72–1.65)	0.681	1.11 (0.73–1.68)	0.627
Subtype						
Astrocytic tumors	122/223	89/157	1.04 (0.74–1.46)	0.838	1.12 (0.79–1.59)	0.513
Ependymoma	33/223	28/157	1.21 (0.70–2.08)	0.501	1.15 (0.66–1.99)	0.632
Neuronal and mixed	16/223	9/157	0.80 (0.34–1.85)	0.601	0.82 (0.35–1.92)	0.652
Embryonal tumors	7/223	4/157	0.81 (0.23–2.82)	0.743	0.96 (0.27–3.41)	0.943
Clinical stages						
I	79/223	71/157	1.28 (0.87–1.87)	0.208	1.35 (0.92–1.99)	0.127
II	42/223	30/157	1.02 (0.61–1.69)	0.956	1.02 (0.61–1.70)	0.953
III	21/223	15/157	1.02 (0.51–2.03)	0.967	0.97 (0.48–1.97)	0.939
IV	36/223	15/157	0.59 (0.31–1.12)	0.106	0.68 (0.35–1.31)	0.249
I+II	121/223	101/157	1.19 (0.85–1.66)	0.318	1.22 (0.87–1.70)	0.254
III+IV	57/223	30/157	0.75 (0.46–1.22)	0.242	0.77 (0.47–1.26)	0.295

*Adjusted for age and gender, omitting the corresponding stratify factor. CI:

Confidence interval; OR: Odds ratio; XPF: Xeroderma pigment